S-(-)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl] pyridine | 162542-91-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: S-(-)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl] pyridine
• 英文别名: (S)-CDP-840；CT1731；(S)-(-)-4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine；CDP840；4-[(S)-2-(3-Cyclopentyloxy-4-methoxy-phenyl)-2-phenyl-ethyl]-pyridine；4-[(2S)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine
• CAS: 162542-91-8
• 化学式: C₂₅H₂₇NO₂
• 分子量: 373.495
• InChiKey: UTUUPXBCDMQYRR-QHCPKHFHSA-N

物化性质

• 沸点：
  489.9±45.0 °C(Predicted)
• 密度：
  1.122±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-[(E)-2-(3-cyclopentyloxy-4-methoxyphenyl)-1-[(S)-(4-methylphenyl)sulfinyl]ethenyl]pyridine 、 alkaline earth salt of/the/ methylsulfuric acid 在 bis(acetylacetonate)nickel(II) 、 锌 作用下， 生成 4-[(2R)-2-(3-环戊基氧基-4-甲氧基苯基)-2-苯基乙基]吡啶 、 S-(-)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl] pyridine
  参考文献：
  名称：

  Ni-catalyzed nucleophilic conjugate additions of Grignard and organozincate reagents to substituted 4-vinylpyridines. General synthesis of phosphodiesterase IV inhibitors

  摘要：

  Alkyl, aryl, and vinyl Grignard reagents were added to olefin II under Ni(acac)(2) or Cl2Ni(PPh3)(2) catalysis to give products with the general formula I in 74-95% yield. Organozincates gave similar results with Ni(acac), as the catalyst, (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(97)10217-4

文献信息

• ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES
  申请人：Marfat Anthony

  公开号：US20070161681A1

  公开（公告）日：2007-07-12

  Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of the formula: wherein the substituents are as defined in the specification.

  以下化合物可用作PDE4的抑制剂，用于治疗由嗜酸性粒细胞的活化和脱颗粒调控的疾病，特别是哮喘、慢性支气管炎和慢性阻塞性肺疾病，其化学式如下：其中取代基如规范中所定义。
• REMEDIES/PREVENTIVES FOR CHRONIC SKIN DISEASE
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1810692A1

  公开（公告）日：2007-07-25

  The present invention provides: a therapeutic and/or preventive agent for chronic skin diseases which comprises (a) a phosphodiesterase (PDE)-IV inhibitor or a pharmaceutically acceptable salt thereof and (b) a steroid agent as active ingredients; a therapeutic and/or preventive agent for chronic skin diseases to be administered simultaneously or separately with an interval which comprises (a) a PDE-IV inhibitor or a pharmaceutically acceptable salt thereof and (b) a steroid agent, as active ingredients; a kit for treating and/or preventing chronic skin diseases characterized by comprising (a) a first component comprising a PDE-IV inhibitor or a pharmaceutically acceptable salt thereof and (b) a second component comprising a steroid agent; and the like.

  本发明提供了一种治疗和/或预防慢性皮肤病的药剂，其活性成分包括(a)磷酸二酯酶(PDE)-IV抑制剂或其药学上可接受的盐和(b)类固醇制剂；一种治疗和/或预防慢性皮肤病的药剂，可与包括(a)磷酸二酯酶(PDE)-IV抑制剂或其药学上可接受的盐和(b)类固醇制剂在内的活性成分同时或单独施用；一种治疗和/或预防慢性皮肤病的试剂盒，其特征在于包括(a)由 PDE-IV 抑制剂或其药学上可接受的盐组成的第一组分和(b)由类固醇制剂组成的第二组分；等等。
• PHARMACEUTICAL COMPOSITION
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1813284A1

  公开（公告）日：2007-08-01

  The present invention provides a pharmaceutical composition comprising (a) a phosphodiesterase (PDE)-IV inhibitor or a pharmaceutically acceptable salt thereof and (b) an immunosuppressant, a therapeutic and/or preventive agent for chronic skin diseases comprising (a) a PDE-IV inhibitor or a pharmaceutically acceptable salt thereof and (b) an immunosuppressant, a therapeutic and/or preventive agent for chronic skin diseases to be administered simultaneously or separately with an interval comprising (a) a PDE-IV inhibitor or a pharmaceutically acceptable salt thereof and (b) an immunosuppressant, as active ingredients,; and the like.

  本发明提供了一种药物组合物，包含(a)磷酸二酯酶(PDE)-IV抑制剂或其药学上可接受的盐和(b)免疫抑制剂，一种用于慢性皮肤病的治疗和/或预防剂，包含(a)PDE-IV抑制剂或其药学上可接受的盐和(b)免疫抑制剂、一种用于慢性皮肤病的治疗和/或预防剂，可同时或分别与一种间隔给药，其活性成分包括(a) 一种 PDE-IV 抑制剂或其药学上可接受的盐和(b) 一种免疫抑制剂；等。
• Synergistic combination
  申请人：Nycomed GmbH

  公开号：EP2193808A1

  公开（公告）日：2010-06-09

  The invention relates to the combined administration of PDE inhibitors and β2 adrenoceptor agonists for the treatment of respiratory tract disorders.

  本发明涉及联合使用 PDE 抑制剂和 β2 肾上腺素受体激动剂治疗呼吸道疾病。
• Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes
  申请人：Pfizer Products Inc.

  公开号：EP1229034B1

  公开（公告）日：2005-04-13